Skip to main content
SAGE - PMC COVID-19 Collection logoLink to SAGE - PMC COVID-19 Collection
letter
. 2021 Apr;100(2 Suppl):188S–191S. doi: 10.1177/0145561320950491

Safety and Impact of Nasal Lavages During Viral Infections Such as SARS-CoV-2

Thomas Radulesco 1,2,, Jerome R Lechien 1,3,4, Sven Saussez 3, Claire Hopkins 5, Justin Michel 1,2
PMCID: PMC7453155  PMID: 32853040

Much has been stated about the potential risks of nasal lavages (NL) during the coronavirus disease 2019 (COVID-19) pandemic for COVID-19 patients and surrounding people. Several otolaryngological societies recommended to limit NL, supposing it may be associated with viral spread to lower airway. 1 On the contrary, recent studies suggested that NL may be beneficial in upper viral respiratory infectious diseases. In order to take stock of this issue, we conducted a short literature review to address 4 main questions:

What Are the Potential Benefits of NL to COVID-19 Patients?

Beneficial effects on nasal mucosal

Ions, pH and tonicity may influence epithelial cell function in vitro. Isotonic solutions with slightly alkaline pH optimize trophic and functional recovery of the respiratory epithelium. 2 In chronic rhinosinusitis, saline solutions improve mucociliary clearance 3 without altering commensal bacteria. 4 These actions may aid recovery of the nasal epithelium after viral injury and reduce associated symptoms of rhinitis.

Direct antiviral effects

Recently, Ramalingam et al reported that antiviral activity against viral infections can be augmented by increasing availability of NaCl. 5 Nasal lavages containing carrageenans, which are natural emulsifiers derived from red seaweed, seemed to reduce the Influenza A viral load in nasal secretions and positive effects on mucosal barrier function. 6,7 Hendley and Gwaltney reported lower virus concentrations after saline NL in rhinovirus infections. 8 Regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Carrouel et al found the use of a mouth rinses with local nasal applications that contain β-cyclodextrins combined with flavonoids agents reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. 9

The use of copper-enhanced NL seems to be efficient to decrease viral spread and contamination, especially regarding SARS-CoV-2. 10,11 Human coronavirus 229E was rapidly inactivated on a range of copper alloys at low copper concentration, suggesting a specific antiviral effect. 12,13 In fact, exposure to copper destroyed the viral genomes and irreversibly affected virus morphology, including disintegration of envelope and dispersal of surface spikes. 14 Copper also inactivates SARS coronavirus, bacteria, and yeast in the air after 20 minutes of exposure. 15 A recent study has proposed that the combination of copper, N-acetylcysteine, colchicine, and nitric oxide with antiviral agents may be a treatment option for SARS-CoV-2-positive patients. 16

Washing and reduction of viral load in enhancing recovery

Computational fluid dynamics studies demonstrate that all nasal regions are reached when using a head tilt position of 45 °C forward for NL, 17 especially with large-volume irrigations, 18 suggesting good mechanical efficiency of NL in washing the nose.

Nasal mucosa have high viral loads and include cells expressing proteases responsible for virus entry (such as angiotensin-converting enzyme 2 and TMPRSS2 for SARS-CoV-2), 19,20 The upper airway has shown to be a reservoir for descending bacterial or viral infection to the lung. 21 The nose can be considered as a site of virus replication, accumulation, and human body entry. 22 Interestingly, NL tends to decrease nasal viral loads and, therefore, could reduce systemic or bronchopulmonary dissemination. 8 Nasal lavages are commonly used treatments in the upper respiratory tract infections and can decrease duration of illness in common cold. 3,23,24

Given the potential benefits summarized above, nasal saline irrigation may enhance recovery in patients known to be infected with COVID-19. Patients are currently being recruited to a randomized controlled trial to evaluate the benefits to COVID-19 patients, although no results are yet available. 25

What Are the Potential Benefits of NL to Personal Contacts/Healthcare Workers Caring for COVID-19 Patients?

When properly performed, NL have shown to decrease household transmission in other viral disease. 26 The potential direct antiviral actions and reduction in viral load have led to proposals that use in patients with COVID-19 may reduce risk of nosocomial transmission. It has been proposed that regular use of NL in COVID-19 patients may reduce risk of transmission to household contacts or Healthcare Workers (HCWs), particularly if used before aerosol-generating procedures (AGPs). 27 It has also been suggested that HCWs involved in the care of COVID-19 patients could use NL with povidone–iodine before and after patient contact, particularly for high-risk procedures. 27

In asking a patient or currently healthy HCW to perform an intervention aimed at protecting others, it is important to discuss potential side effects of the intervention.

What Are the Potential Harms of NL to Patients With COVID-19?

Risk of toxicity

Although nasal saline irrigation has been shown to have no detrimental effects on olfaction, additives to NL solutions may cause anosmia, which would be difficult to detect in trials of COVID-19 patients, where olfactory dysfunction is highly prevalent. A number of agents have been shown to cause anosmia if delivered intranasally, such as zinc gluconate and sinus surfactant solutions. 28 Although the safety of povidone–iodine has been evaluated in vitro, at concentrations above 5% it is known to be ciliotoxic. 29 Its use in mouthwash and nasal spray in COVID-19-infected patients prior to dental and other AGPs has been widely promoted in the absence of rigorous in vivo evaluation. 7,30

Risk of bronchopulmonary dissemination

To date, no study suggested that NL is associated with lower respiratory disorders.

What Are the Potential Harms of NL to Personal Contacts/HCWs Caring For COVID-19 Patients?

Risk of droplet spread and surface contamination

Irrigation is likely to generate droplets potentially carrying viruses. Sinus irrigation devices, mostly composed by plastic, can harbor viruses for hours: van Doremalen et al showed that SARS-CoV-2 is very stable on plastic and remains viable up to 72 hours. 12 As the COVID-19 status of most of patients using NL is unknown, specific measures should be undertaken to protect personal contacts or HCWs. 31

Protective measures

  • – Clean the inside and outside of the NL device thoroughly with soap and water. For a deeper clean of components of the device that come into contact with the nose, clean with 70% isopropyl alcohol or concentrated white vinegar, rinse, and then leave to it dry before next use. Some commercial products may be suitable for sterilization in the microwave but must be replaced if there is any sign of degradation of plastic components.

  • – Self-irrigation is important, avoiding viral exposure to others.

  • – Ventilate the room: being able to remain suspended in the air, small droplets were shown to permit SARS-CoV-2 detection in ambient air for 3 hours. 12 Guidelines on air exchanges per hour required for airborne contaminant removal have been edited by CDC. 32

  • – Perform household cleaning, disinfection of high-touch surfaces, and hand hygiene. The United States Environmental Protection Agency and the CDC (Center for Disease Control and Prevention) published a list of recommended household disinfectants. 33

Consistent with current guidance, these measures will help to limit viral spreading.

Conclusion

Taken together, these data suggest that NL can be continued during viral infection when respecting strict conditions of use and hygienic measures. Moreover, properly performed, large-volume NL with specific composition such as copper or povidone–iodine could limit viral contamination and spreading. In vitro, in vivo, and in silico studies must confirm these data.

Acknowledgments

To Pr Vincent Couloigner and Dr Philippe Contencin.

Authors’ Note: T.R. and J.R.L. are joint first authors. C.H. and J.M. are joint senior authors.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

  • 1.CONSULTATIONS ET TRAITEMENTS MEDICAMENTEUX EN RHINOLOGIE EN CONTEXTE D’EPIDEMIE COVID-19. 2020. Accessed July 15, 2020. https://www.sforl.org/wp-content/uploads/2020/03/AFR-SFORL-COVID-19-V2.pdf.
  • 2. Bastier PL, Lechot A, Bordenave L, Durand M, de Gabory L. Nasal irrigation: from empiricism to evidence-based medicine. A review. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(5):281–285. [DOI] [PubMed] [Google Scholar]
  • 3. de Gabory L, Escabasse V, Boudard P, et al. Prospective, randomized, controlled, open-label study to compare efficacy of a mineral-rich solution vs normal saline after complete ethmoidectomy. Eur Arch Otorhinolaryngol. 2019;276(2):447–457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Liu CM, Kohanski MA, Mendiola M, et al. Impact of saline irrigation and topical corticosteroids on the postsurgical sinonasal microbiota: topical therapies and the sinonasal microbiota. Int Forum Allergy Rhinol. 2015;5(3):185–190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Ramalingam S, Cai B, Wong J, et al. Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep. 2018;8(1):13630. doi:10.1038/s41598-018-31936-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Leibbrandt A, Meier C, König-Schuster M, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320. doi:10.1371/journal.pone.0014320 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Ramezanpour M, Murphy J, Smith JLP, Vreugde S, Psaltis AJ. In vitro safety evaluation of human nasal epithelial cell monolayers exposed to carrageenan sinus wash. Int Forum Allergy Rhinol. 2017;7(12):1170–1177. doi:10.1002/alr.22021 [DOI] [PubMed] [Google Scholar]
  • 8. Hendley JO, Gwaltney JM. Viral titers in nasal lining fluid compared to viral titers in nasal washes during experimental rhinovirus infection. J Clin Virol. 2004;30(4):326–328. [DOI] [PubMed] [Google Scholar]
  • 9. Carrouel F, Conte MP, Fisher J, et al. COVID-19: a recommendation to examine the effect of mouthrinses with β-cyclodextrin combined with citrox in preventing infection and progression. J Clin Med. 2020;9(4):1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Huang S, Constant S, De Servi B, et al. In vitro safety and performance evaluation of a seawater solution enriched with copper, hyaluronic acid, and eucalyptus for nasal lavage. Med Devices (Auckl). 2019;12:399–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Radulesco T, Lechien JR, Chiesa-Estomba CM, et al. Copper enhanced nasal saline irrigations: a safe potential treatment and protective factor for COVID-19 infection? Rhinol Online. 2020;3(3):87–88. [Google Scholar]
  • 12. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567. doi:10.1056/NEJMc2004973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Borkow G, Gabbay J. Copper as a biocidal tool. Curr Med Chem. 2005;12(18):2163–2175. doi:10.2174/0929867054637617 [DOI] [PubMed] [Google Scholar]
  • 14. Warnes SL, Little ZR, Keevil CW. Human coronavirus 229E remains infectious on common touch surface materials. mBio. 2015;6(6):e01697–15. doi:10.1128/mBio.01697-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. He H, Dong X, Yang M, et al. Catalytic inactivation of SARS coronavirus, Escherichia coli and yeast on solid surface. Catal Commun. 2004;5(3):170–172. doi:10.1016/j.catcom.2003.12.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19: the potential role of copper and n-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2. Vivo Athens Greece. 2020;34(3 suppl):1567–1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Inthavong K, Ma J, Shang Y, et al. Geometry and airflow dynamics analysis in the nasal cavity during inhalation. Clin Biomech (Bristol, Avon). 2019;66:97–106. doi:10.1016/j.clinbiomech.2017.10.006 [DOI] [PubMed] [Google Scholar]
  • 18. de Gabory L, Reville N, Baux Y, Boisson N, Bordenave L. Numerical simulation of two consecutive nasal respiratory cycles: toward a better understanding of nasal physiology: simulation of nasal physiology. Int Forum Allergy Rhinol. 2018;8(6):676–685. [DOI] [PubMed] [Google Scholar]
  • 19. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Fothergill JL, Neill DR, Loman N, Winstanley C, Kadioglu A. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat Commun. 2014;5:4780. doi:10.1038/ncomms5780 [DOI] [PubMed] [Google Scholar]
  • 22. Butowt R, Bilinska K. SARS-CoV-2: Olfaction, Brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11(9):1200–1203. doi:10.1021/acschemneuro.0c00172 [DOI] [PubMed] [Google Scholar]
  • 23. Cabaillot A, Vorilhon P, Roca M, Boussageon R, Eschalier B, Pereirad B. Saline nasal irrigation for acute upper respiratory tract infections in infants and children: a systematic review and meta-analysis. Paediatr Respir Rev. 2020;S1526–0542(20)30016–6. doi:10.1016/j.prrv.2019.11.003 [DOI] [PubMed] [Google Scholar]
  • 24. King D, Mitchell B, Williams CP, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;(4):CD006821. doi:10.1002/14651858.CD006821.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Participant Information Sheet. 2020. Accessed July 15, 2020. https://www.ed.ac.uk/files/atoms/files/elvis_covid-19_participant_information_sheet_v4.0_01june2020.pdf.
  • 26. Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. 2019;9(1):1015. doi:10.1038/s41598-018-37703-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. . Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as « Personal Protective Equipment » for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020;105:104724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Davidson TM, Smith WM. The Bradford hill criteria and zinc-induced anosmia: a causality analysis. Arch Otolaryngol Head Neck Surg. 2010;136(7):673–676. [DOI] [PubMed] [Google Scholar]
  • 29. Kim JH, Rimmer J, Mrad N, Ahmadzada S, Harvey RJ. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol. 2015;129(suppl 1):S45–S50. doi:10.1017/S0022215114002746 [DOI] [PubMed] [Google Scholar]
  • 30. Challacombe SJ, Kirk-Bayley J, Sunkaraneni VS, Combes J. Povidone iodine. Br Dent J. 2020;228(9):656–657. doi:10.1038/s41415-020-1589-4 [DOI] [PubMed] [Google Scholar]
  • 31.Should You Still Rinse Your Sinuses During The COVID-19 Outbreak? 2020. Accessed July 15, 2020. https://www.henryford.com/blog/2020/03/should-you-rinse-your-sinuses-during-covid.
  • 32.Guidelines for Environmental Infection Control in Health-Care Facilities. 2003. Accessed July 15, 2020. https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html.
  • 33.List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19). Accessed July 15, 2020. https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2-covid-19.

Articles from Ear, Nose, & Throat Journal are provided here courtesy of SAGE Publications

RESOURCES